NCT01893177View on ClinicalTrials.gov

Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14)

PHASE3CompletedINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

August 31, 2013

Study Completion Date

August 31, 2013

Conditions
Influenza
Interventions
BIOLOGICAL

Inflexal V

Intramuscular administration (M. deltoideus) of a single dose of 0.5 mL Inflexal V

Trial Locations (1)

6864

CROSS Research S.A. - Phase I Unit, Arzo

All Listed Sponsors
lead

Crucell Holland BV

INDUSTRY

NCT01893177 - Re-licensing Study to Assess Inflexal V Formulated With WHO Recommended Influenza Strains (2013-14) | Biotech Hunter | Biotech Hunter